Proceedings From the First International Workshop at Sidra Medicine:'Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development', 15th–16th February 2019, Doha, Qatar

Autor: Guerrouahen B., Elnaggar M., Al-Mohannadi A., Kizhakayil D., Bonini C., Benjamin R., Brentjens R., Buchholz C. J., Casorati G., Ferrone S., Locke F. L., Martin F., Schambach A., Turtle C., Veys P., van der Vliet H. J., Maccalli C., Benabdellah K., Bos T., Cugno C., Johnston I., Mohamed A., Ponterio E., Abu Rasheed H. M., Roelands J., Taha R. Y.

Publikováno v: The EICCI Faculty Group 2021, ' Proceedings From the First International Workshop at Sidra Medicine : “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar ', Frontiers in Immunology, vol. 11, 589381 . https://doi.org/10.3389/fimmu.2020.589381
Digibug. Repositorio Institucional de la Universidad de Granada
instname
Digibug: Repositorio Institucional de la Universidad de Granada
Universidad de Granada (UGR)
Frontiers in immunology, 11:589381
Frontiers in Immunology, Vol 11 (2021)
Frontiers in Immunology

The progress in the isolation and characterization of tumor antigen (TA)-specific T lymphocytes and in the genetic modification of immune cells allowed the clinical development of adoptive cell therapy (ACT). Several clinical studies highlighted the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e31d5dca100c7285451baaf17f735ef9
https://research.vumc.nl/en/publications/0d3f3ecb-ab4b-401d-ad6a-70f0a6c59ca6

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.